Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33


Recombinant human granulocyte- colony stimulating factor in women with unexplained recurrent pregnancy losses: a randomized clinical trial.

Eapen A, Joing M, Kwon P, Tong J, Maneta E, De Santo C, Mussai F, Lissauer D, Carter D; RESPONSE study group .

Hum Reprod. 2019 Mar 1;34(3):424-432. doi: 10.1093/humrep/dey393.


Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.

Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C.

J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17.


Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.


Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy.

Bokori-Brown M, Metz J, Petrov PG, Mussai F, De Santo C, Smart NJ, Saunders S, Knight B, Pastan I, Titball RW, Winlove CP.

Front Oncol. 2018 Nov 27;8:553. doi: 10.3389/fonc.2018.00553. eCollection 2018.


Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C.

Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32028. [Epub ahead of print]


Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma.

De Santo C, Cheng P, Beggs A, Egan S, Bessudo A, Mussai F.

J Hematol Oncol. 2018 May 18;11(1):68. doi: 10.1186/s13045-018-0612-6.


Tumor-Derived GM-CSF Promotes Granulocyte Immunosuppression in Mesothelioma Patients.

Khanna S, Graef S, Mussai F, Thomas A, Wali N, Yenidunya BG, Yuan C, Morrow B, Zhang J, Korangy F, Greten TF, Steinberg SM, Stetler-Stevenson M, Middleton G, De Santo C, Hassan R.

Clin Cancer Res. 2018 Jun 15;24(12):2859-2872. doi: 10.1158/1078-0432.CCR-17-3757. Epub 2018 Mar 30.


The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.

De Santo C, Booth S, Vardon A, Cousins A, Tubb V, Perry T, Noyvert B, Beggs A, Ng M, Halsey C, Kearns P, Cheng P, Mussai F.

Int J Cancer. 2018 Apr 1;142(7):1490-1502. doi: 10.1002/ijc.31170. Epub 2017 Dec 26.


Arginine auxotrophic gene signature in paediatric sarcomas and brain tumours provides a viable target for arginine depletion therapies.

Vardon A, Dandapani M, Cheng D, Cheng P, De Santo C, Mussai F.

Oncotarget. 2017 Jun 29;8(38):63506-63517. doi: 10.18632/oncotarget.18843. eCollection 2017 Sep 8.


Neuroblastoma arginine addiction subverts the anticancer immune response.

De Santo C, Mussai F.

Oncoimmunology. 2015 Nov 11;5(2):e1078967. eCollection 2016 Feb.


Molecular basis and current strategies of therapeutic arginine depletion for cancer.

Fultang L, Vardon A, De Santo C, Mussai F.

Int J Cancer. 2016 Aug 1;139(3):501-9. doi: 10.1002/ijc.30051. Epub 2016 Apr 15. Review.


Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity.

Mussai F, Egan S, Hunter S, Webber H, Fisher J, Wheat R, McConville C, Sbirkov Y, Wheeler K, Bendle G, Petrie K, Anderson J, Chesler L, De Santo C.

Cancer Res. 2015 Aug 1;75(15):3043-53. doi: 10.1158/0008-5472.CAN-14-3443. Epub 2015 Jun 8.


Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target.

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, Loke J, Pratt G, U KP, Lo A, Ng M, Kearns P, Cheng P, De Santo C.

Blood. 2015 Apr 9;125(15):2386-96. doi: 10.1182/blood-2014-09-600643. Epub 2015 Feb 20.


Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment.

Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, Qureshi A, Dazzi F, Vyas P, Cerundolo V.

Blood. 2013 Aug 1;122(5):749-58. doi: 10.1182/blood-2013-01-480129. Epub 2013 Jun 3.


Interaction between invariant NKT cells and myeloid-derived suppressor cells in cancer patients: evidence and therapeutic opportunities.

Mussai F, De Santo C, Cerundolo V.

J Immunother. 2012 Jul;35(6):449-59. doi: 10.1097/CJI.0b013e31825be926. Review.


Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A.

De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V.

Nat Immunol. 2010 Nov;11(11):1039-46. doi: 10.1038/ni.1942. Epub 2010 Oct 3.


In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.

Ugel S, Zoso A, De Santo C, Li Y, Marigo I, Zanovello P, Scarselli E, Cipriani B, Oelke M, Schneck JP, Bronte V.

Cancer Res. 2009 Dec 15;69(24):9376-84. doi: 10.1158/0008-5472.CAN-09-0400.


Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans.

De Santo C, Salio M, Masri SH, Lee LY, Dong T, Speak AO, Porubsky S, Booth S, Veerapen N, Besra GS, Gröne HJ, Platt FM, Zambon M, Cerundolo V.

J Clin Invest. 2008 Dec;118(12):4036-48. doi: 10.1172/JCI36264. Epub 2008 Nov 13.


B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo.

Barral P, Eckl-Dorna J, Harwood NE, De Santo C, Salio M, Illarionov P, Besra GS, Cerundolo V, Batista FD.

Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8345-50. doi: 10.1073/pnas.0802968105. Epub 2008 Jun 11.


Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V.

J Clin Invest. 2006 Oct;116(10):2777-90.


Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention.

Bronte V, Cingarlini S, Marigo I, De Santo C, Gallina G, Dolcetti L, Ugel S, Peranzoni E, Mandruzzato S, Zanovello P.

Immunol Invest. 2006;35(3-4):327-57. Review.


Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

De Santo C, Serafini P, Marigo I, Dolcetti L, Bolla M, Del Soldato P, Melani C, Guiducci C, Colombo MP, Iezzi M, Musiani P, Zanovello P, Bronte V.

Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90. Epub 2005 Mar 7.


Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.

De Palma R, Marigo I, Del Galdo F, De Santo C, Serafini P, Cingarlini S, Tüting T, Lenz J, Basso G, Milan G, Zanovello P, Bronte V.

Cancer Res. 2004 Nov 1;64(21):8068-76.


Methotrexate for immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation.

Cozzi E, Cadrobbi R, Baldan N, Dedja A, Calabrese F, Castagnaro M, Fante F, Boldrin M, Iacopetti I, Ravarotto L, Carraro P, Bronte V, De Santo C, Busetto R, Plebani M, Cancellotti FM, Rigotti P, Thiene G, Ancona E.

Xenotransplantation. 2003 Nov;10(6):587-95.


Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase.

Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P.

J Immunol. 2003 Dec 15;171(12):6396-405.


Derangement of immune responses by myeloid suppressor cells.

Serafini P, De Santo C, Marigo I, Cingarlini S, Dolcetti L, Gallina G, Zanovello P, Bronte V.

Cancer Immunol Immunother. 2004 Feb;53(2):64-72. Epub 2003 Oct 30. Review.


IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Bronte V, Serafini P, De Santo C, Marigo I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, Colombo MP, Zanovello P.

J Immunol. 2003 Jan 1;170(1):270-8.


Association of responsiveness to the major pollen allergen of Parietaria officinalis with HLA-DRB1* alleles: a multicenter study.

D'Amato M, Scotto d'Abusco A, Maggi E, Menna T, Sacerdoti G, Maurizio SM, Iozzino S, De Santo C, Oreste U, Tosi R, D'Amato G, Baltadijeva D, Bjorkstén B, Freidhoff LR, Lahoz C, Marsh DG, Rashef A, Ruffilli A.

Hum Immunol. 1996 Apr;46(2):100-6.


Characterization of a dominant antigenic determinant of Par o I encoded by recombinant DNA.

Scotto d'Abusco AS, De Santo C, Menna T, Coscia MR, Oreste U, Geller-Bernstein C, Ruffilli A.

Clin Exp Allergy. 1996 Feb;26(2):223-31.


The direct effect of the thyroid hormone on cardiac chronotropism.

Valente M, De Santo C, de Martino Rosaroll P, Di Maio V, Di Meo S, De Leo T.

Arch Int Physiol Biochim. 1989 Dec;97(6):431-40.


Modulation of the heart rate by thyroid hormone in the newborn rat.

Valente M, de Martino Rosaroll P, De Santo C, Di Meo S, De Leo T.

Arch Int Physiol Biochim. 1989 Dec;97(6):427-30.


A new method of preparation of a pure heart mitochondrial fraction.

de Martino Rosaroll P, Rossi MA, De Santo C, Mazza C, Sansone R, Di Meo S, De Leo T.

Boll Soc Ital Biol Sper. 1987 Oct 31;63(10):897-901. No abstract available.


The morphology of the adrenal cortex in the hypothyroid rat.

Valente M, de Martino Rosaroll P, De Santo C, Mazza C, Pietropaolo VA, Sansone R, De Leo T, Paino G.

Boll Soc Ital Biol Sper. 1987 Oct 31;63(10):855-60. No abstract available.


Supplemental Content

Loading ...
Support Center